Forest Licenses Novexel’s Novel Broad-Spectrum Beta-Lactamase Inhibitor
By Business Review Editor
Pharma Deals Review: Vol 2008 Issue 93 (Table of Contents)
Published: 8 Mar-2008
DOI: 10.3833/pdr.v2008.i93.210 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Novexel and Forest Laboratories Holdings entered into licensing agreement to develop, manufacture and commercialize Novexel’s intravenous beta-lactamase inhibitor, NXL104, in combination with Forest’s ceftraroline, an injectable broad-spectrum cephalosporin active against MRSA and multi-drug resistant Streptococcus pneumoniae...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS